Experience

Cerberus Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Founding Member

  • Mar 2022 - Present



University of California, San Francisco

• United States
• Higher Education
• 700 & Above Employee

• Doctoral Student

  • Sep 2018 - Mar 2021

  Proud PhD dropout pursuing more exciting path towards pioneering the biotechnology industry back home in Indonesia Proud PhD dropout pursuing more exciting path towards pioneering the biotechnology industry back home in Indonesia



Massachusetts Institute of Technology

• United States
• Higher Education
• 700 & Above Employee

• Teaching Assistant

  • Feb 2018 - Jun 2018

  Teaching assistant for Harvey Lodish and Jianzhu Chen in 7.371 Underlying Principles to Novel Biotherapeutics. Leading discussion, giving lecture and helping with course administration. Teaching assistant for Harvey Lodish and Jianzhu Chen in 7.371 Underlying Principles to Novel Biotherapeutics. Leading discussion, giving lecture and helping with course administration.



Boston Children's Hospital

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Associate

  • Dec 2017 - Jun 2018

  Engineered red blood cells via enzymatic and genetic modification as therapeutic platform to treat multiple diseases such as type 1 diabetes, multiple sclerosis, hemophilia, atheroclerosis and obesity. Engineered red blood cells via enzymatic and genetic modification as therapeutic platform to treat multiple diseases such as type 1 diabetes, multiple sclerosis, hemophilia, atheroclerosis and obesity.



Whitehead Institute

• United States
• Research Services
• 200 - 300 Employee

• Research Associate

  • Dec 2017 - Jun 2018

  In collaboration with Hidde Ploegh's and Harvey Lodish's Labs to develop a theraputic platform using red blood cells as systemic carriers for proteins and small molecules as treatment for multiple diseases. In collaboration with Hidde Ploegh's and Harvey Lodish's Labs to develop a theraputic platform using red blood cells as systemic carriers for proteins and small molecules as treatment for multiple diseases.



Massachusetts Institute of Technology

• United States
• Higher Education
• 700 & Above Employee

• Undergraduate Student Researcher, Ploegh and Lodish Lab

  • Feb 2014 - Jun 2017

  Lodish Lab • Engineered red blood cells as vehicles to deliver diverse array of therapeutics for inducing immune tolerance in autoimmune diseases, neutralizing botulinum toxin, neutralizing ebola virus and lowering cholesterol. • Equipped red blood cells with EGF-A peptide and nano-bodies against PCSK9 via enzymatic and genetic modification • Tested the ability of engineered red blood cells in lowering cholesterol levels via blood transfusion and stem cell transplantation treatment in hypercholesterolemia mouse model • Wrote a research summary and filed a patent application of the novel cholesterol lowering therapeutic • Presented the novel cholesterol blockbuster project in a seminar talk and poster presentation at the MIT Undergraduate Biology Symposium, MIT Biological Engineering Symposium and the Gordon Research Conference for Atherosclerosis 2017 Ploegh Lab • Engineered red blood cell to covalently carry antigenic peptide for inducing tolerance against autoimmune diseases • Evaluated the transfusion of red blood cells carrying self-antigen peptides in maintaining normoglycemia in type 1 diabetes (T1D) mouse model and preventing multiple sclerosis in EAE mouse model • Collected tissue samples from EAE and T1D mouse model and analyzed the results by immunohisto- chemistry, immunofluorescence, western blot and flow cytometry • Conducted adaptive MOG-specific CD4+ T transplant to EAE mouse model for studying T cell activation and exhaustion in autoimmune diseases via single cell RNA sequencing Show less